BIRC2
Baculoviral IAP repeat-containing protein 2
As of the edition of 20 October 2026, BIRC2 (baculoviral IAP repeat-containing protein 2, UniProt Q13490) has 4 drugs tested at it and 11 companies on the list, 10 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13490
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 29
- Disease areas
- Cancer; Blood and lymph; Digestive system; Lungs and airways; Hormones; Pregnancy and women's health; Urinary and reproductive; Immune system
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 4 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Xevinapant | Stopped | Phase 3 | none listed |
| Birinapant | Stopped | Phase 2 | none listed |
| LCL-161 | Stopped | Phase 2 | none listed |
| GDC-0152 | Stopped | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 10 |
| Engaged | 1 |
| Total on the list | 11 |
| Company | Route |
|---|---|
| Roche | Route A |
| Merck KGaA | Route A |
| Debiopharm | Route A |
The other 8 companies at BIRC2
In the product11 companies in all; 8 are not named here, and no score is.
See the 11 companies at BIRC2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.